Cosette Pharmaceuticals Announces The Approval And Launch Of First Generic Version Of RECTIV Ointment, 0.4%, With 180 Days Competitive Generic Therapy Exclusivity; RECTIV Is Registered Trademark Of AbbVie
Portfolio Pulse from Benzinga Newsdesk
Cosette Pharmaceuticals has received FDA approval for the first generic version of RECTIV ointment, 0.4%, with 180 days of exclusivity. This marks Cosette's 24th product launch and 3rd CGT approval in two years. The launch leverages Cosette's R&D and manufacturing capabilities in Lincolnton, NC. U.S. annual sales of nitroglycerin ointment 0.4% were approximately $21.2 million. RECTIV is a registered trademark of AbbVie.
February 22, 2024 | 1:53 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AbbVie, the owner of the RECTIV trademark, may face competition from Cosette's newly approved generic version, potentially impacting sales.
The approval and launch of a generic version of RECTIV by Cosette Pharmaceuticals could lead to increased competition in the market for nitroglycerin ointment, potentially affecting AbbVie's sales and market share for this product. Given the specific mention of RECTIV and AbbVie's ownership, the impact is directly relevant. The importance is moderate, considering the size of the market for this specific product relative to AbbVie's overall portfolio. The confidence level reflects the typical market dynamics following the introduction of generic competitors.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 80